why biotechs need to worry about generics, too, page-7

No worries, rustyone.

I was pointing out that the quote LeeTV produced was not
relevant...that particular change in legislation is only for changes in the structure of a drug itself, which could lead to a 12 year extension.

I remember AS saying that delivery in the UNS device may
extend protection by one or two years(as in your original post), and I've no reason to doubt that.